China IND Application of CMS (00867)¡¯s Innovative Drug Latanoprost Eye Drops was Accepted
2021-01-14 20:50

On January 14, the IND application of CMS¡¯s innovative drug Latanoprost Eye Drops was accepted by the Center for Drug Evaluation, NMPA. Latanoprost Eye Drops is a once-a-day, BAK-free novel 0.005% latanoprost ophthalmic formulation, which is indicated for reduction of elevated intraocular pressure in patients with open-angle glaucoma, or ocular hypertension.


Latanoprost Eye Drops has been approved for marketing by the U.S. FDA under the brand name XelprosTM. As a prostaglandin drug, which is one of the first-line treatments for open-angle glaucoma or ocular hypertension, the product is developed with LipixelleTM technology that dissolves latanoprost with non-ionic surfactants, and can achieve BAK-free delivery to avoid the potential ocular damage caused by long-term use of BAK.

The prevalence of primary open-angle glaucoma with ocular hypertension in China is estimated to be 1.5% to 2%, with more than 20 million people. We look forward to the launch of Latanoprost Eye Drops in China, so as to bring a safe and effective treatment option for patients with related indications. In the future, as a candidate of the Group¡¯s innovative drugs in the ophthalmology line, the product will create synergy effects with other ophthalmic drugs, improving the competitive advantage of the Group in the ophthalmology line and injecting impetus for the continuous development of Group's ophthalmology business.